Scynexis, Inc. and R-Pharm have entered into an agreement granting R-Pharm exclusive rights to develop and commercialize SCY-078 in Russia and several other markets. Scynexis retains the rights to market the compound in The Americas, Europe and Asia. SCY-078 is an oral glucan synthase inhibitor being developed for the treatment of systemic fungal diseases such as candidemia and aspergillosis.   R-Pharm will develop and register SCY-078 in its territories including Russia, The Commonwealth of Ind...